Aug 12, 2019

Blue Origin protests Air Force launch competition

An artist's illustration of Blue Origin's New Glenn rocket in flight. Photo: Blue Origin

Blue Origin is protesting the Air Force's methods for finding 2 companies to launch national security payloads through the mid-2020s.

Why it matters: If chosen, the companies will effectively lock in billions of dollars in revenue, undertaking a 60/40 split of national security launches between 2022 and 2026.

The big picture: Blue Origin, SpaceX, Northrop Grumman and United Launch Alliance are all expected to compete to launch these payloads, and it would be a boon for their bottom lines.

  • "The demand for rockets really can't support all the providers. So it's a kind of vicious fight to stay alive," John Logsdon, founder of the Space Policy Institute at George Washington University, told Axios of the competition earlier this year.

The state of play: In a fact sheet, Blue Origin claims that the Air Force's request for proposals is "flawed" and favors incumbents — SpaceX and United Launch Alliance — that have launched missions for the Air Force in recent years.

  • A redacted copy of the protest filed with the U.S. Government Accountability Office and obtained by Axios accuses the Air Force of using "ambiguous" selection criteria, making it difficult to write a competitive proposal.
  • The protest also claims that the way the request for proposals stands now will result in a "duopoly" that restricts competition.
  • A source with knowledge of the situation told Axios that the protest comes after conversations with the Air Force expressing these concerns.

Context: If chosen, Blue Origin would use its New Glenn rocket to launch these national security payloads. That rocket is expected to make its first flight in 2021, after the government agency has already chosen its launch providers.

Meanwhile, the Air Force awarded Blue Origin, Northrop Grumman and United Launch Alliance millions of dollars in 2018 to aid in the development of their new launch systems and meet stringent demands for national security-related launches.

Go deeper: Space companies fight for cash with rockets on the line

Go deeper

Coronavirus dashboard

Illustration: Aïda Amer/Axios

  1. Global: Total confirmed cases as of 2 p.m. ET: 5,453,784 — Total deaths: 345,886 — Total recoveries — 2,191,310Map.
  2. U.S.: Total confirmed cases as of 2 p.m. ET: 1,651,254 — Total deaths: 97,850 — Total recoveries: 366,736 — Total tested: 14,163,915Map.
  3. World: Top Boris Johnson aide defends himself after allegations he broke U.K. lockdown — WHO suspends trial of hydroxychloroquine over safety concerns.
  4. 2020: Trump threatens to move Republican convention from North Carolina — Joe Biden makes first public appearance in two months.
  5. Public health: Officials are urging Americans to wear masks over Memorial Day.
  6. Economy: White House economic adviser Kevin Hassett says it's possible the unemployment rate could still be in double digits by November's election — Charities refocus their efforts to fill gaps left by government.
  7. What should I do? Hydroxychloroquine questions answeredTraveling, asthma, dishes, disinfectants and being contagiousMasks, lending books and self-isolatingExercise, laundry, what counts as soap — Pets, moving and personal healthAnswers about the virus from Axios expertsWhat to know about social distancingHow to minimize your risk.
  8. Other resources: CDC on how to avoid the virus, what to do if you get it, the right mask to wear.

Subscribe to Mike Allen's Axios AM to follow our coronavirus coverage each morning from your inbox.

Updated 35 mins ago - Politics & Policy

Joe Biden makes first public appearance in over two months

Photo: Oliver Douliery/AFP via Getty Images

Former Vice President Joe Biden made his first in-person appearance in over two months on Monday to honor Memorial Day by laying a wreath at a Delaware veterans park, AP reports.

Why it matters: Biden, the Democratic Party's presumptive nominee, has taken the unprecedented step of campaigning from his home during the coronavirus pandemic, ever since canceling a rally in Cleveland on March 10.

WHO temporarily suspends trial of hydroxychloroquine over safety concerns

Photo: Fabrice Coffrini/AFP via Getty Images

The World Health Organization is temporarily pausing tests of the anti-malarial drug hydroxychloroquine as a coronavirus treatment in order to review safety concerns, the agency's director-general Tedros Adhanom Ghebreyesu said Monday.

Why it matters: The decision comes after a retrospective review published in The Lancet found that coronavirus patients who took hydroxychloroquine or its related drug chloroquine were more likely to die or develop an irregular heart rhythm that can lead to sudden cardiac death, compared to those who did nothing.